Stopped: As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.
The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.
Age range
12 Months – 24 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Emergency Room Visits
Timeframe: 12 months CA through 60 months CA
Number of Hospitalizations
Timeframe: 12 months CA through 60 months CA
Incidence of Signs and Symptoms of Respiratory Disease
Timeframe: 12 months CA through 60 months CA
Number of Days of Respiratory Medication Use
Timeframe: 12 months CA through 60 months CA
Total Number of Days on Home Respiratory Technology use
Timeframe: 12 months CA through 60 months CA
Number of Participants With Adverse Events (AEs)
Timeframe: 12 months CA through 60 months CA